Personalized Off-The-Shelf Immunotherapy

Bria-OTS™: Personalized Off-the-Shelf Immunotherapy

BriaCell Phase 1/2 Study of Bria-OTS™, also known as Bria-BRES™, in metastatic breast cancer is open

The Phase 1/2 clinical study is listed on ClinicalTrials.gov as NCT06471673.

• Bucket trial with additional cancer indications planned
• Enhanced version (Bria-OTS+™) scheduled to enter the clinic 1H2025 starting with Bria-Pros™ (prostate cancer)

==========================================================================================================================

• We believe Bria-IMT™ is most effective in human leukocyte antigens (HLA) – type matched patients
• Bria-OTS™ is engineered to express 15 unique HLA types through 4 independent cell lines
• Provides matched treatment to greater than 99% of patients
• Simple saliva test provides HLA matched personalized off-the-shelf Bria-OTS™ immunotherapy
• HLA matched off-the-shelf therapy is faster and less costly than other expensive and complex personalized immunotherapies
• BriaCell received a Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) to further develop Bria-OTS™
• Ongoing collaboration with the NCI to investigate the Bria-OTS™ mechanism action
• BriaCell has secured numerous US and international patents for Bria-OTS™
• Similar immunotherapies are in development for prostate cancer (Bria-Pros™), lung cancer (Bria-Lung™), and melanoma (Bria-Mel™)